BR112022022830A2 - Métodos e composições para tratamento de anemia usando armadilhas de ligante de actriib e inibidores de mtor - Google Patents

Métodos e composições para tratamento de anemia usando armadilhas de ligante de actriib e inibidores de mtor

Info

Publication number
BR112022022830A2
BR112022022830A2 BR112022022830A BR112022022830A BR112022022830A2 BR 112022022830 A2 BR112022022830 A2 BR 112022022830A2 BR 112022022830 A BR112022022830 A BR 112022022830A BR 112022022830 A BR112022022830 A BR 112022022830A BR 112022022830 A2 BR112022022830 A2 BR 112022022830A2
Authority
BR
Brazil
Prior art keywords
methods
anemia
compositions
treatment
mtor inhibitors
Prior art date
Application number
BR112022022830A
Other languages
English (en)
Portuguese (pt)
Inventor
Acar Melih
Schwickart Martin
Jupelli Madhulika
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112022022830A2 publication Critical patent/BR112022022830A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022022830A 2020-05-15 2021-05-14 Métodos e composições para tratamento de anemia usando armadilhas de ligante de actriib e inibidores de mtor BR112022022830A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025955P 2020-05-15 2020-05-15
PCT/US2021/032434 WO2021231851A1 (en) 2020-05-15 2021-05-14 Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors

Publications (1)

Publication Number Publication Date
BR112022022830A2 true BR112022022830A2 (pt) 2022-12-13

Family

ID=78525025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022830A BR112022022830A2 (pt) 2020-05-15 2021-05-14 Métodos e composições para tratamento de anemia usando armadilhas de ligante de actriib e inibidores de mtor

Country Status (11)

Country Link
US (1) US20230210827A1 (https=)
EP (2) EP4649961A3 (https=)
JP (1) JP2023526590A (https=)
KR (1) KR20230010641A (https=)
CN (1) CN115551487A (https=)
AU (1) AU2021273065A1 (https=)
BR (1) BR112022022830A2 (https=)
CA (1) CA3177632A1 (https=)
IL (1) IL298156A (https=)
MX (1) MX2022014080A (https=)
WO (1) WO2021231851A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
CN104968801B (zh) 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CA3001654A1 (en) * 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
MA45811A (fr) * 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
WO2018185341A1 (en) * 2017-04-07 2018-10-11 Ospedale San Raffaele S.R.L. Regulator of bmp-smad signaling and uses thereof
PL3638243T3 (pl) * 2017-06-14 2025-02-10 Celgene Corporation Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości
EP4041243A4 (en) * 2019-09-27 2023-10-18 Disc Medicine, Inc. METHODS OF TREATMENT OF ANEMIA OF CHRONIC DISEASE

Also Published As

Publication number Publication date
EP4649961A2 (en) 2025-11-19
IL298156A (en) 2023-01-01
CA3177632A1 (en) 2021-11-18
EP4149441A1 (en) 2023-03-22
MX2022014080A (es) 2022-12-07
JP2023526590A (ja) 2023-06-22
CN115551487A (zh) 2022-12-30
US20230210827A1 (en) 2023-07-06
WO2021231851A1 (en) 2021-11-18
EP4649961A3 (en) 2026-02-25
EP4149441A4 (en) 2024-03-13
KR20230010641A (ko) 2023-01-19
AU2021273065A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
EA202190630A1 (ru) Способы комбинированной терапии
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
BR112022022830A2 (pt) Métodos e composições para tratamento de anemia usando armadilhas de ligante de actriib e inibidores de mtor
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
MY209831A (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
MX2017012729A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA201690027A1 (ru) Ингибиторы ido
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
BR112018069628A2 (pt) métodos para tratamento de tumor sólido
BR112018017195A2 (pt) terapia de combinação de smc para o tratamento do câncer
NO20083240L (no) Sammensetninger og fremgangsmater for forebygging og behandling av kakeksia
EA201591599A1 (ru) Ингибиторы ido
EA201890157A1 (ru) Способы лечения эпителиоидноклеточных опухолей
WO2023023345A3 (en) Methods of using activin receptor type ii signaling inhibitors
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
BR112023026660A2 (pt) Armadilhas do ligante fator de crescimento transformante-beta para o tratamento de doença
BR112022020628A2 (pt) Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe
BR112018073858A2 (pt) métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
BR112022025801A2 (pt) Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]